CLDN18.2 ADC Improves Survival in Later Line Gastric Cancer

Company Takeda; Innovent Biologics Event Type Phase 3 interim analysis Modality Antibody-drug conjugate (exatecan payload) Asset Arcotatug tavatecan (IBI343/TAK-921) Target CLDN18.2 Disease Area CLDN18.2-positive advanced gastric or GEJ cancer Summary The randomized 464-patient G-HOPE-001 trial of Innovent-originated, Takeda-licensed arcotatug tavatecan met both overall survival and…